<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03614767</url>
  </required_header>
  <id_info>
    <org_study_id>17/30334</org_study_id>
    <nct_id>NCT03614767</nct_id>
  </id_info>
  <brief_title>Sacral Neuromodulation &amp; Urodynamics</brief_title>
  <official_title>Assessment of Predictive Role of Urodynamics in Sacral Neuromodulation Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universiteit Antwerpen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the field of urology, sacral neuromodulation (SNM) is a well-accepted, second-line,
      minimally invasive treatment for patients with overactive bladder dry (OABD) or wet (OABW),
      and for patients with non-obstructive urinary retention (NOUR).

      Long-term vary between 50-60%. This study examines whether urodynamics can be used as a
      predictor for successful SNM therapy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bladder volume</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change in bladder volume is measured before and after test procedure for sacral neuromodulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in bladder sensation</measure>
    <time_frame>3 weeks</time_frame>
    <description>Bladder sensation is measured by a slider (indicating bladder fullness scaled from 0 to 100) before and after test procedure for sacral neuromodulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ice water test</measure>
    <time_frame>3 weeks</time_frame>
    <description>Ice water is infused in the bladder and incontinence upon insertion of the ice water is assessed before and after sacral neuromodulation</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Non-obstructive Urinary Retention</condition>
  <arm_group>
    <arm_group_label>Successes</arm_group_label>
    <description>Patients with &gt;50% improvement during test procedure of sacral neuromodulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Failures</arm_group_label>
    <description>Patients with &lt;50% improvement during test procedure of sacral neuromodulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>urodynamics</intervention_name>
    <description>Bladder filling and pressure is measured by the insertion of probes within the bladder, urethra and anorectum.</description>
    <arm_group_label>Failures</arm_group_label>
    <arm_group_label>Successes</arm_group_label>
    <other_name>Ice water test</other_name>
    <other_name>Slider</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with overactive bladder or non-obstructive urinary retention.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overactive bladder

          -  Non-obstructive urinary retention

        Exclusion Criteria:

          -  Neurogenica disorder (e.g. cerebrovascular accident, spinal cord injury)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Stefan De Wachter, MD PhD FEBU</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan De Wachter, MD PhD FEBU</last_name>
    <phone>8215934</phone>
    <phone_ext>323</phone_ext>
    <email>stefan.dewachter@antwerpen.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of antwerp</name>
      <address>
        <city>Antwerpen</city>
        <state>Edegem</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan De Wachter, MD PhD FEBU</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>October 13, 2019</last_update_submitted>
  <last_update_submitted_qc>October 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiteit Antwerpen</investigator_affiliation>
    <investigator_full_name>Donald Vagan√©e</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Urinary Retention</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

